Mary V. Relling, PharmD
Mary V. Relling, PharmD

Mary V. Relling, PharmD

Member, St. Jude Faculty

  • Chair, Pharmaceutical Sciences Department

Departments

Education

BS – University of Arizona
PharmD – University of Utah College of Pharmacy

Honors & Awards

  • 2012 Mentor of the Year, St. Jude Postdoctoral Association,
  • 2010 Award for Clinical Service, University of North Carolina, Institute for Pharmacogenomics and Individualized Therapy
  • 2009 Institute of Medicine
  • 2009 Team Science Award, American Association for Cancer Research
  • 2009 Pediatric Oncology Award and Lecture Recipient, American Society of Clinical Oncology
  • 2007 Alumni Association Professional Achievement Award, University of Arizona
  • 2002 Therapeutic Frontiers Award Lecture Award, American College of Clinical Pharmacy
  • 2002 Gerhard Levy Distinguished Lecture Award, SUNY, Buffalo
  • 2002 Russell R. Miller Award, American College of Clinical Pharmacy
  • 1998 Leon I. Goldberg Young Investigator Award, American Society for Clinical Pharmacology and Therapeutics

Research Interests

  • Antineoplastic pharmacokinetics and pharmacodynamics in children
  • Clinical implementation of pharmacogenomic testing
  • Host- and treatment-related risk factors affecting antileukemic therapy

Improving the drug therapy of childhood leukemia

Selected Publications

Ramsey LB , Janke LJ , Edick MJ, Cheng C, Williams RT , Sherr CJ , Evans WE , Relling MV, Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness in a Murine Model. Pharmacogenetics and Genomics 2014 (in press). 

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM. Development and use of active clinical decision support for preemptice pharmacogenomics. J AM Med Inform AssocAug 2013. PMID23978487.

Janke LJ, Liu C, Vogel P, Kawedia J, Boyd KL, Funk AJ, Relling MV. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol Jul;183(1):19-25, 2013. PMCID:PMC3702740.

Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, Stoddard A, Yang W, Smith C,Fernandez CA, Cross SJ, Haidar C, Baker DK, Howard SC, Evans WE, Broeckel U, Relling MV. A clinician driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharm Ther 92(5):563-6, 2012. PMCID:PMC3589522.

Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119:1658-64, 2012. PMCID: PMC3286344.

Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89:387-91, 2011. PMCID: PMC3098761.

Relling MV, Klein TE. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464-7, 2011. PMCID: PMC3098762.

Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, Camitta BM, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 43:237-41, 2011. PMCID: PMC3104508.

Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, Neale G, Howard SC, Evans WE, Pui CH, Relling MV. Pharmacokinetic, pharmacodynamic and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood December 10, 2010.

Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol April 20, 2010.

Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV. Treatment of childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med Jun 25;360(26):2730-41, 2009.

Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009.

Yang L, Boyd K, Kaste SC, Kamdem LK, Rahija RJ, Relling MV. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 27:169-175, 2008.

Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds S, Trevino L, French D, Campana D, Downing J, Evans WE, Pui C, Devidas M, Bowman W, Camitta B, Willman CL, Davies S, Borowitz M, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009.

Hartford C, Vasquez E, Schwab M, Edick MJ, Rehg JE, Grosveld G, Pui CH, Evans WE, Relling MV. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 67: 4965-72, 2007.

Jones TS, Yang W, Evans WE, Relling MV. Using HapMap tools in pharmacogenomic discovery: The thiopurine methyltransferase polymorphism. Clin Pharmacol Ther 81:729-34, 2007.

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-64, 2007.

Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood109:4151-7, 2007.

Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, Johnson JA, Krauss RM, McLeod HL, Ratain MJ, Relling MV, Ring HZ, Schuldiner AR, Weinshilboum RM, Weiss ST. Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749-57, 2006.

French D, Wilkinson MR, Yang W, de chaisemartin L, Cook EH, Das S, Ratain MJ, Evans WE, Downing JR, Pui CH, Relling MV. Global gene expression as a function of germline genetic variation. Hum Mol Genet 14:1621-1629, 2005.

Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Pui CH, Evans WE, Relling MV. Pharmacogenetics of Outcome in Children with Acute Lymphoblastic Leukemia. Blood 105: 4752-4758, 2005.

Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, Howard S, Ribeiro R, Sandlund JT, Pui Ch, Kaste SC. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22:3930-3936, 2004.

Holleman A, Cheok MH, den Boer ML, Yang W, Veerman A, Kazemier KM, Pei D, Cheng C, Pui CH,Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene Expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351:533-542, 2004.

Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468, 2004.

Blanco JG, Edick MJ, Relling MV. Etoposide induces chimeric Mll gene fusions. FASEB J 18:173-175, 2004.

Blanco JG, Dervieux T, Edick M, Mehta PK, Rubnitz JE, Shurtleff S, Raimondi SC, Behm FG, Pui CH,Relling MV. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98:10338-10343, 2001.

Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001.

Ratain MJ, Relling MV. Gazing into a crystal ball: cancer therapy in the post-genomic era. Nat Med 7:285-287, 2001.

Relling MV, Pui C-H, Sandlund JT, Rivera GK, Hancock ML, Boyett JB, Evans WE. Chronic anticonvulsant therapy reduces the efficacy of chemotherapy for childhood acute lymphoblastic leukemia. Lancet 356:285-290, 2000.

Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999.

Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491, 1999.

Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, Kun LE, Walter AW, Evans WE, Pui C-H. High incidence of secondary brain tumors related to irradiation and antimetabolite therapy. Lancet 354:34-39, 1999.

Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H. Conventional versus individualized doses of chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998.

Last update: March 2014